Nestlé Health Science has announced its collaboration with a colorado based cannabis manufacturer to launch its first broad-spectrum CBD formulation. The subsidiary of Nestlé, a worldwide food and beverage company, has plans to start producing and selling CBD based products in Europe.
The new CBD softgel formulation will boast a unique delivery system that has been christened VESIsorb. The patented delivery system is a lipid-based formula used in products with low absorption to increase their bioavailability. This way, users will enjoy enhanced effectiveness of the formulation.
In a statement by the Fort Collins headquartered Geocann, the initial batch of large scale CBD soft gels was produced earlier September using only European resources. The biomass was produced in Slovenia and then formulated into soft gels utilizing the drug delivery technology in Switzerland where Nestle has its headquarters.
Jesse Lopez, CEO and founder of Geocann, said that he was proud to partner with Nestlé’s Europe healthcare professional brands, especially after their success in the US. He further reiterated that Nestles’s science-backed and clinically-proven validation of hemp products is a crucial milestone for the industry and provides credibility to the therapeutic value of VESIsorb® formulated cannabinoids.
Neste launched its raid on the US CBD market in August last year pioneering its range of THC free CBD products. The Swiss food giant owns the Garden of Life brand under which the US products are sold. They include soft gels, CBD liquids, and sprays.
The September 10 statement released by Geocann to announce the launch further indicates that they have concluded several toxicology tests on the new products. The results will be out in the open later this year in regards to the company’s FDA’s requirements for Generally Recognized As Safe (GRAS) application.
In its bid to conquer Europe, Nestle leverages peer-reviewed and published CBD study on the safety of its products data by Geocann.